Search filters

Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 372
  • 1194
  • 567
  • 28
  • 43
  • 2
  • 1127
  • 1195
  • 5

Found 1200 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 1
The outlined research study is not of therapeutic intent, involving only the collection of blood, cerebrospinal fluid, and tissue samples to evaluate pharmacokinetics and resistance.
99 years or below
All genders
Phase 2
This is a Phase 2 open-label, single-arm design with dose escalation by subject cohort and with the potential for individual titration (dose increase or decrease) within each cohort. Five PTG-300 dose levels/regimens are planned to be tested for each subpopulation of beta-thalassemia (NTD and TD) on separate arms: Cohort 1: …
 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
18 years - 80 years
All genders
Phase 2
Interventional
The purpose of this study is to determine the effects of sirolimus in patients (males or females aged 18-80) with idiopathic multicentric Castleman Disease (iMCD) who are either unable to tolerate siltuximab or tocilizumab, or have failed, relapsed, or are refractory to this treatment. Subjects will take sirolimus daily for …
 Towards predicting the analgesic response to ibuprofen following third-molar extraction
18 years - 64 years
All genders
NSAIDs like ibuprofen are pain relievers that are commonly used to reduce pain after dental procedures.  Patients who have their impacted third molar teeth taken out usually experience pain one to three hours after surgery and require pain relievers for at least 2 days. Most people (about 70-90%) experience good …
99 years or below
All genders
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people in the US and around the world. Over the last 20 years, the catheter based AF ablation procedure has been widely adopted. However, the long-term success in paroxysmal AF is 50% and as low as 20% in …
18 years - 99 years
All genders
Phase 1
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
 PTAAK- study of pulse wave velocity evaluation  tacrolimus time in therapeutic range and co-efficient of tacrolimus variation of African American kidney transplant recipients receiving immediate release tacrolimus capsules (IR-Tac) or extended release tacrolimus tablets (LCPT)
18 years - 75 years
All genders
Phase 4
The primary purpose of this study is to evaluate the pulse wave velocity and vascular compliance measurements at the beginning and the end of the study in African American kidney transplant recipients taking either Envarsus XR® (extended release tacrolimus) tablets administered once-daily after transplantation or immediate release generic tacrolimus capsules …
99 years or below
All genders
Phase 3
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
99 years or below
All genders
Phase 2
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
211 - 220 of 1200